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LEVONORGESTREL INTRAUTERINE SYSTEM AND CERVICAL CANCER. 
CLINICAL DIFFICULTIES
Introduction. In recent years, intrauterine systems releasing levonorgestrel became popular. They are a reliable and safe 
means of contraception. However, the hormonal effects of such systems sometimes mask the clinical manifestations of intercurrent 
diseases, including those manifested by irregular uterine bleeding.
Case Description: The emergence of diagnostic difficulties in the occurrence of cervical cancer in two women who used 
intrauterine systems releasing levonorgestrel.
Conclusion. Proper evaluation of irregular vaginal bleeding, including cervical cytology, is a prerequisite for all women who 
are carriers of intrauterine systems releasing levonorgestrel.
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ЛЕВОНОРГЕСТРЕЛ-ВНУТРІШНЬОМАТКОВА СИСТЕМА І РАК ШИЙКИ МАТКИ. КЛІНІЧНІ ТРУДНОЩІ
Вступ. В останні роки набули популярності внутрішньоматкові системи, що вивільняють левоноргестрел. Вони є на-
дійним та безпечним засобом контрацепції. Однак гормональні ефекти подібних систем іноді маскують клінічні прояви 
інтеркурентних захворювань, в тому числі тих, що проявляються нерегулярною матковою кровотечею.
Опис випадку: труднощі діагностики при виникненні раку шийки матки у двох жінок, які використовували внутрішньо-
маткові системи, що вивільняють левоноргестрел.
Висновок. Належна оцінка нерегулярної вагінальної кровотечі, включаючи цитологію шийки матки – обо'вязкова умова 
для усіх жінок, які є носіями внутрішньоматкових систем, що вивільняють левоноргестрел.
Ключові слова: внутрішньоматкові системи, що вивільняють левоноргестрел; контрацепція; нерегулярні кровотечі; 
рак шийки матки.
ЛЕВОНОРГЕСТРЕЛ-ВНУТРИМАТОЧНАЯ СИСТЕМА И РАК ШЕЙКИ МАТКИ. КЛИНИЧЕСКИЕ ТРУДНОСТИ
Введение. В последние годы стали популярными внутриматочные системы, высвобождающие левоноргестрел. Они 
являются надежным и безопасным средством контрацепции. Однако гормональные эффекты подобных систем иногда 
маскируют клинические проявления интеркуррентных заболеваний, в том числе проявляющихся нерегулярным маточным 
кровотечением.
Описание случая: сложности диагностики при возникновении рака шейки матки у двух женщин, использовавших 
внутриматочные системы, высвобождающие левоноргестрел.
Вывод. Надлежащая оценка нерегулярного вагинального кровотечения, включая цитологию шейки матки – обязатель-
ное условие для всех женщин, которые являются носителями внутриматочных систем, высвобождающих левоноргестрел.
Ключевые слова: внутриматочные системы, высвобождающие левоноргестрел; контрацепция; нерегулярные крово-
течения; рак шейки матки.
INTRODUCTION. The frequency of unplanned 
pregnancies remains quite high worldwide. About 35–50 % 
of all pregnancies are unintended, with a higher proportion 
among adolescents and young women belonging to certain 
racial and ethnic minorities or with a low level of education 
and income. Intrauterine hormone-releasing systems (IHRS) 
are more effective than other IUDs of the first and second 
generation. Levonorgestrel (LNG) releasing intrauterine 
systems remain the most effective and promising IHRS, 
used worldwide [1–7].
LNG as a component of HCV was chosen because it 
is one of the most potent progestins, has a pronounced 
affinity for progesterone receptors, and exhibits 100 % 
biological activity. It is a synthetic gestagene from the group of 
19-norsteroids, the most active of the known gestagens. LNG 
has strong antiestrogenic and antigonadotropic effects and 
weak androgenic properties. LNG is not metabolized in the 
endometrium as fast as progesterone [1, 4]. Its contraceptive 
mechanism is based on:
 – changes in the viscosity and chemical properties of 
cervical mucus (prevention of sperm penetration, as well 
as pathogens);
 – impaired sperm function, including their motility 
(significant suppression of endometrial function can also 
contribute to impaired sperm migration into the fallopian 
tubes);
 – changes in the structure of the endometrium 
(inhibition of proliferative processes; suppression of 
the mitotic activity of endometrial and myometrial cells; 
decidual-like stroma reaction; thickening and fibrosis of 
the vessel walls; thrombosis in capillaries; decreased 
vascularization; development of atrophic processes and 
amenorrhea);
 – suppression of antiperistaltic activity of the fallopian 
tubes;
 – suppression of the hypothalamic-pituitary function 
(mild inhibition of LH secretion, changes in the ovulation 
process and corpus luteum function).
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The most common adverse effects of LNG include 
changes in blood loss, spotting, oligomenorrhea, amenorrhea, 
vulvovaginitis, genital tract infections, pelvic infections, 
ovarian cysts, dysmenorrhea, breast pain, expulsion IUD 
(full or partial),  headache, abdominal pain, pelvic pain, 
migraine, back pain, blue mood, depression, nausea, acne, 
hirsutism [4].
LMG-IUS could be an alternative to hysterectomy and 
endometrial ablation for menorrhagia especially among 
perimenopausal women [3, 5]. However, since irregular 
bleeding is quite common amongst the users of LNG IUS 
in the first months after its introducing, this symptom could 
mask underlying cervical pathology, e.g. cervical cancer. We 
faced two such cases in our practice:
Case 1. Ukrainian female, S., 41 year-old, had 
irregular uterine bleeding irresponsible for combined oral 
contraceptives during last 18 months.  PAP test was negative. 
No abnormalities were found during inspection of the cervix. 
Patient had intramural fibroid in the fundus with the size 4.3 
× 4,9 cm. LNG IUS was introduced for menorrhagia control. 
However in two weeks patient came back to a clinic with the 
complains to abdominal pain. Pelvic inflammatory disease 
was diagnosed, atibiotics non-steroid anti-inflammatory drugs 
were recommended. In two months later patient suffered from 
irregular uterine bleeding again. Because such manifestation 
could occur during 2–3 months after LNG-IUS introduction 
she got instructions to make a new appointment if continuous 
bleeding. Advanced medical examination was performed. 
PAP-test demonstrated suspicious lesions for neoplasia 
with abnormal vessels. The diagnosis of cervical cancer in 
stage IIA was approved histologically. The first PAP smear 
was false-negative due to blood staining but perhaps this 
lady had cervical cancer even before LNG-IUS inserting. A 
radical extended hysterectomy was performed in this case.
Case 2. A 32-year-old woman requested insertion of 
LNG-IUS due to family issues. She did not report any medical 
problems, PAP smear was performed and was negative at 
the moment of admission.  In a half of year LNG-IUS was 
removed due to continuous uterine bleeding. Patient was 
recommended to use oral contraceptives. The irregular 
bleeding was attributed to LNG-IUS, no PAP-test was 
performed. Only in three  months after second appointment 
the patient was examined again. We found tenderness during 
bimanual palpation and cervical ulceration  suspected for 
neoplasia. Cervical cytology showed moderate dysplasia 
and micro-invasive adenosquamous carcinoma of the cervix 
(stage IIB) was detected after biopsy. Combined treatment 
(radical hysterectomy with pelvic node dissection plus 
radiotherapy) was performed.
DISCUSSION. Regularily the use of an intrauterine 
system  can halve the risk of cervical cancer. There is good 
reason to believe that the use of an intrauterine system 
containing levonorgestrel can reduce the growth of human 
papillomavirus into cervical cancer. However, in some 
cases vaginal bleeding in carriers of LNG-IUS could be by 
mistake accepted as an adverse effect of LNG. Relatively 
low sensitivity of PAP smear (50–80 %) could produce 
false-negative results, However, repeating PAP test could 
significantly improve its diagnostic value.
The advantage of Papanicolaou staining is that the 
method allows to evaluate the degree of maturity of the 
cytoplasm, while revealing well the nuclei of atypical cells. 
The technique allows to diagnose pathology in the early 
stages, when almost 100 % cure is possible. In traditional 
cytology, a smear is prepared manually. Such a smear 
contains not only mucous cells, but also blood elements, 
mucus, pathogens (if any), which can complicate the study 
and lead to an incorrect assessment of the results. Atypical 
cells can be masked by layered cell elements. All these 
shortcomings cause not very high information content of 
the traditional test. To eliminate errors in the preparation of 
smears and their test study, modern medical equipment for 
conducting liquid cytology could be used.
The main advantage of liquid cytology is an advanced 
automated smear preparation technique. The material is 
taken by a special design cyto-brush, which allows to get 
material from all areas of the cervix. All material is placed 
in a special vial with a stabilizer, in which it is stored for a 
sufficiently long time, and can be re-examined if necessary.
CONCLUSIONS. 
1. Irregular bleeding requires advanced examination 
including repeated PAP-test.
2. Liquid citology method could be a good alternative to 
a regular PAP smear.
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